Go to Samples

Novartis Pharmaceuticals Corporation
Kisqali
Oncology
Indications and Usage
Early Breast Cancer
KISQALI is indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence.
Advanced or Metastatic Breast Cancer
KISQALI is indicated for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with:
- an aromatase inhibitor as initial endocrine-based therapy; or
- fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy.
More than 200,000 clinicians have integrated PrescriberPoint into their clinical workflows















HOW IT WORKS
The easy way to access samples
Create Free AccountRequest, track, and manage samples from multiple brands
Connect with a RepHave access to pharma representatives in one place to request your samples
Get your SampleManage your reps and samples in one place
WHO IS PRESCRIBERPOINT
Increasing patient access to medications they need
At PrescriberPoint, we're revolutionizing how healthcare providers get patients the medications they need. We craft solutions that help providers address the challenges in patient access and improve outcomes.200K+Visitors Each Month
100K+Engagements Each Month
1M+Resources Viewed
WHAT HCPS ARE SAYING
FAQs
All you need to know to order samples
Currently, PrescriberPoint is available only in the U.S, but we are excited to expand our reach in the future! Stay connected by following us or signing up for our newsletter to get the latest updates, including announcements about new market launches.